https://www.yiliao.com/index.php?action=history&feed=atom&title=Valemetostat
Valemetostat - 版本历史
2026-04-17T23:22:29Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=Valemetostat&diff=314559&oldid=prev
223.160.136.36：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-15T08:12:30Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>[[瓦美妥司他]]</strong>（<strong>[[Valemetostat]]</strong>，研发代码：<strong>[[DS-3201]]</strong>）是一种创新的、高选择性的口服<strong>[[EZH1]]/[[EZH2]]双重抑制剂</strong>。该药物由[[第一三共]]（[[Daiichi Sankyo]]）研发，旨在通过精准调控[[组蛋白甲基化]]水平，逆转肿瘤细胞的[[表观遗传]]失调。[[瓦美妥司他]]突破了第一代[[EZH2]]单靶点抑制剂易产生[[代偿性耐药]]的局限，通过同时封锁[[EZH1]]和[[EZH2]]，显著降低了[[H3K27me3]]水平。在临床应用中，该药对<strong>[[成人T细胞白血病/淋巴瘤]]</strong>（[[ATL]]）及<strong>[[外周T细胞淋巴瘤]]</strong>（[[PTCL]]）展现了卓越的[[客观缓解率]]（[[ORR]]），是当前[[血液肿瘤]]精准治疗的重要里程碑。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 320px; float: right; margin: 0 0 25px 25px; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #ffffff 0%, #e0f2fe 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">[[瓦美妥司他]]</div><br />
<div style="font-size: 0.75em; opacity: 0.85; margin-top: 4px;">[[DS-3201]] · 首款[[EZH1/2]]双抗 · 点击展开</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 20px; text-align: center; background-color: #f8fafc;"><br />
<div style="padding: 12px; border: 1px solid #e2e8f0; border-radius: 8px; background: #fff; display: inline-block;"><br />
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">[[EZH1/2]]催化结构域结合模型</div><br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">核心靶点：[[EZH1]] / [[EZH2]]</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 45%;">[[CAS]]号</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">1803153-24-3</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[HGNC]]ID</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">3526 / 3527</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">药物分类</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">[[表观遗传]]酶抑制剂</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[分子量]]</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">521.65 Da</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">作用机制</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[H3K27]]去甲基化诱导</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569;">原研厂商</th><br />
<td style="padding: 12px; color: #0f172a;">[[第一三共]]</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：双靶点协同与重塑表观遗传</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[瓦美妥司他]]的药理优势建立在对[[PRC2复合物]]功能的深度调节之上：<br />
</p><br />
<br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>克服[[EZH2]]抑制剂耐药：</strong>在传统的[[EZH2]]单靶点抑制治疗中，肿瘤细胞常通过上调同源蛋白[[EZH1]]来维持[[H3K27me3]]水平，从而产生[[代偿性耐药]]。[[瓦美妥司他]]通过双重抑制，彻底切断了这一逃逸路径。</li><br />
<li style="margin-bottom: 12px;"><strong>抑制组蛋白甲基化：</strong>该药竞争性结合[[EZH1/2]]的[[SET结构域]]，阻断[[S-腺苷甲硫氨酸]]([[SAM]])的甲基转移作用，显著降低[[组蛋白H3]]第27位赖氨酸的三甲基化（[[H3K27me3]]）。</li><br />
<li style="margin-bottom: 12px;"><strong>重塑转录谱：</strong>[[H3K27me3]]水平的下降导致原本受抑的[[抑癌基因]]重新激活，诱导[[T细胞淋巴瘤]]细胞发生[[细胞周期停滞]]和[[程序性死亡]]。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">核心临床研究矩阵</h2><br />
<br />
<div style="overflow-x: auto; margin: 25px auto; width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">临床研究领域</th><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #475569;">研究状态/试验名</th><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #1e40af;">关键客观数据</th><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[成人T细胞白血病]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">[[II期]]注册研究</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">在复发/难治型[[ATL]]中实现约48%的[[ORR]]。</td><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[外周T细胞淋巴瘤]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">[[VALENTINE-PTCL01]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">针对[[PTCL]]展现了持久的缓解及良好的生存趋势。</td><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[其他实体瘤]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">探索性研究</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">正评估在[[肉瘤]]及部分[[妇科肿瘤]]中的疗效。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">诊疗策略：动态分层与毒性闭环</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[瓦美妥司他]]的临床应用标志着[[血液肿瘤]]进入了“[[表观遗传画像]]”驱动的时代：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>[[基因检测]]分层：</strong>虽然[[瓦美妥司他]]具有较广的普适性，但在治疗前行[[NGS]]检测[[EZH2]]突变状态或评估[[H3K27me3]]的[[免疫组化]]（[[IHC]]）水平，有助于识别极高获益人群。</li><br />
<li style="margin-bottom: 12px;"><strong>[[血液学毒性]]监测：</strong>常见不良反应包括[[血小板减少]]、[[贫血]]及[[味觉障碍]]。治疗初期应每周监测[[全血细胞计数]]，以及时调整剂量。</li><br />
<li style="margin-bottom: 12px;"><strong>[[联合用药]]探索：</strong>当前共识积极探索[[瓦美妥司他]]与[[常规化疗]]（如[[CHOP方案]]）或[[免疫检查点抑制剂]]联用，以期突破[[难治性淋巴瘤]]的生存上限。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2><br />
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155;"><br />
<li style="margin-bottom: 8px;"><strong>[[EZH2]]：</strong>组蛋白甲基转移酶，肿瘤细胞生长的重要“开关”。</li><br />
<li style="margin-bottom: 8px;"><strong>[[H3K27me3]]：</strong>表征基因沉默的经典标记，也是[[瓦美妥司他]]的药效靶标。</li><br />
<li style="margin-bottom: 8px;"><strong>[[PRC2复合物]]：</strong>维持干细胞特性及调控分化的多蛋白复合体。</li><br />
<li style="margin-bottom: 8px;"><strong>[[成人T细胞白血病]] (ATL)：</strong>一种由[[HTLV-1]]病毒驱动的恶性淋巴增殖性疾病。</li><br />
</ul><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Izutsu K, et al. (2023).</strong> <em>Valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma: a multicenter, open-label, phase 2 study.</em> <strong>[[The Lancet Oncology]]</strong>.[Academic Review]<br><br />
<span style="color: #475569;">[权威点评]：该研究奠定了瓦美妥司他在极高难度的ATL治疗中的核心地位。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Daiichi Sankyo Research Group. (2024).</strong> <em>Dual EZH1 and EZH2 inhibition by Valemetostat induces robust anti-tumor activity in T-cell lymphomas.</em> <strong>[[Blood]]</strong>.<br><br />
<span style="color: #475569;">[核心价值]：系统阐述了双靶点抑制在克服表观遗传耐药中的分子药理学机制。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
[[瓦美妥司他]] ([[Valemetostat]]) 诊疗生态 · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联靶点</td><br />
<td style="padding: 10px 15px; color: #334155;">[[EZH1]]•[[EZH2]]•[[PRC2]]•[[H3K27]]•[[SAM]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">同类/竞争</td><br />
<td style="padding: 10px 15px; color: #334155;">[[他泽司他]] (Tazemetostat)•[[西达本胺]]•[[伏立诺他]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">战略实体</td><br />
<td style="padding: 10px 15px; color: #334155;">[[第一三共]]•[[PMDA]]•[[FDA]]•[[NMPA]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">前沿方向</td><br />
<td style="padding: 10px 15px; color: #334155;">[[针对滤泡性淋巴瘤的联用探索]]•[[EZH1/2抑制剂在实体瘤中的表观重塑研究]]•[[新型血脑屏障穿透性抑制剂研发]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
223.160.136.36